Atossa Therapeutics Updates on (Z)-endoxifen Progress
Atossa Therapeutics, Inc. (NASDAQ: ATOS), a dynamic player in the biopharmaceutical sector, has made strides in its mission to innovate treatments in oncology. The company is gearing up to file an Investigational New Drug (IND) application for (Z)-endoxifen, focusing on metastatic breast cancer, supported by its recent selection of a Contract Research Organization (CRO) to streamline development processes.
Financial Overview
The financial results for the third quarter reveal operating expenses of approximately $9.3 million. This figure reflects an increase compared to the previous year's $6.4 million, attributed to heightened research and development efforts on (Z)-endoxifen. CEO Dr. Steven Quay expressed his confidence in the company's direction toward commercialization.
Strategic Developments
Dr. Quay shared that recent initiatives include adopting a financially disciplined approach while repositioning the team to elevate operational efficiency and focus on the critical path to market. The importance of a strong balance sheet was emphasized as the company prepares to engage with the FDA regarding their development plan.
Clinical and Regulatory Advances
In the regulatory landscape, Atossa has engaged the FDA with a Type C meeting request aimed at refining their development strategy for (Z)-endoxifen. The company expects valuable feedback that may shape their approach to drug development and potentially expedite the process toward filing an NDA.
Key Appointments
Atossa has also made strategic appointments, naming Janet R. Rea, MSPH, as Senior Vice President of R&D. With her extensive background in clinical development, she will play a crucial role in leading the charge towards FDA engagement and approval timelines.
Focus on (Z)-endoxifen
(Z)-endoxifen has emerged as a cornerstone of Atossa's therapeutic portfolio. As a highly effective Selective Estrogen Receptor Modulator/Degrader (SERM/D), it shows promise in treating breast cancer due to its ability to act on estrogen receptors, even in resistant tumors. Clinical studies demonstrated a positive tolerance profile among patients.
Ongoing Trials and Future Directions
Atossa's development trajectory for (Z)-endoxifen includes ongoing Phase 2 studies in various settings, emphasizing its application in DCIS and ER+/HER2- patients. The company is committed to optimizing its regulatory approach to open pathways for broader usage in preventing breast cancer among high-risk women.
Intellectual Property Initiatives
To bolster its pipeline, Atossa has announced key patent issuances, including a recent patent in Israel strengthening its market protection for (Z)-endoxifen. This is part of a broader strategy to secure its proprietary innovations across major jurisdictions.
FAQ
1. What is (Z)-endoxifen?
(Z)-endoxifen is a Selective Estrogen Receptor Modulator/Degrader being developed to treat and reduce the risk of breast cancer.
2. How much did Atossa spend in Q3 2025?
Atossa's operating expenses for the third quarter of 2025 were reported as $9.3 million, an increase from the previous year.
3. What recent changes occurred in leadership?
Janet R. Rea was appointed as Senior Vice President of R&D to help accelerate the development of (Z)-endoxifen.
4. What are the expected next steps for (Z)-endoxifen?
Atossa plans to file an IND for (Z)-endoxifen and pursue discussions with the FDA regarding potential expedited pathways for approval.
5. How does Atossa’s patent strategy affect its future?
The patent strategy aims to protect Atossa's innovations, securing a competitive advantage in developing its therapies.
